Should non-nucleoside reverse transcriptase inhibitors be combined?

Drugs in R and D

Volumn 6, Issue 2, 2005, Pages 61-69

  Kappelhoff, Bregt S ^a   Huitema, Alwin D R ^a   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; CALANOLIDE A; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LIVER ENZYME; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; INCIDENCE; INHIBITION KINETICS; INSOMNIA; LIVER DYSFUNCTION; MALAISE; MEDICAL DECISION MAKING; MENTAL DISEASE; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STOMACH DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 16844386197     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506020-00001     Document Type: Review

References (37)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998 Mar; 338 (13): 853-60
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.pdf [Accessed 2004 Nov]
3. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 Dec; 349 (24): 2304-15
4. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003 Sep; 188 (5): 625-34
5. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002 Jul; 288 (2): 169-80
6. Gulick RM, Smeaton LM, D'Aquila RT, et al. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis 2001 Mar; 183 (5): 715-21
7. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003 May; 17 (7): 987-99
8. Cuzin L, Pugliese P, Bugnon F, et al. Triple NRTI vs NNRTI containing regimens as first line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients [abstract no. TuPeB4533]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
9. Moyle G, Nelson MR, Higgs C, et al. An open-label, randomised comparative study of a quadruple NRTI regimen (Trizivir+tenofovir) versus a standard of care 2 class triple therapy regimen (Combivir+efavirenz) as initial therapy for HIV-1 infection. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
10. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev 2002 Jul; 4 (3): 128-39
11. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2004 Apr; 9 (2): 297-9
12. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999 Sep; 25 (3): 225-32
13. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 Jun 19; 353 (9170): 2093-9
14. Kollmann C, Tremblay C, Giguel F, et al. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Antivir Ther 2001 Jun; 6 (2): 143-4
15. Quan Y, Motakis D, Buckheit Jr R, et al. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antivir Ther 1999; 4 (4): 203-9
16. Adkins JC, Noble S. Efavirenz. Drugs 1998 Dec; 56 (6): 1055-64
17. Clarke S, Harrington P, Barry M, et al. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis 2000 Sep; 31 (3): 806-7
18. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995 Mar; 171 (3): 537-45
19. Miller V, De Bethune MP, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998 Dec; 42 (12): 3123-9
20. de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997 Apr; 175 (4): 966-70
21. Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 2004 May; 15 (3): 121-34
22. King RW, Klabe RM, Reid CD, et al. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother 2002 Jun; 46 (6): 1640-6
23. Gu Z, Quart Y, Li Z, et al. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J Biol Chem 1995 Dec; 270 (52): 31046-51
24. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40 (12): 893-905
25. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opin Invest Drugs 1996; 5 (9): 1183-99
26. Lamson M, MacGregor T, Riska P, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways [abstract PI-791]. 100th American Society for Clinical Pharmacology and Therapeutics; 1999 Mar 18-20; San Antonio (TX)
27. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002 Jul; 72 (1): 1-9
28. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 2004; 4 (9): 921-44
29. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001 Jul; 184 (1): 37-42
30. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study [abstract no. 1239]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 29-Nov 2; Washington, DC
31. Olivieri J. Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients. Sex Transm Infect 2002 Feb; 78 (1): 72-3
32. Jordan WC, Jefferson R, Yemofio F, et al. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. J Natl Med Assoc 2003 Dec; 95 (12): 1152-7
33. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 Jan; 15 (1): 71-5
34. Joshi AS, Barret JS, Fiske WD, et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy [abstract no. 1201]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
35. Gey DC, Lorenz T, Brost J, et al. An NRTI-free regimen in HIV-patients with evidence of mitochondrial toxicity: 48 weeks results of a pilot study [abstract no. TuPeB4512]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
36. Arranz-Caso JA, Gorgolas M, Estrada V, et al. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors. HIV Med 2004 Mar; 5 (2): 128-9
37. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004 Apr; 363: 1253-63